Monday, July 15, 2024

Companion Diagnostics Drive Precision Oncology Growth and Accessibility

Similar articles

Companion diagnostic (CDx) tests play a pivotal role in modern oncology by identifying specific biomarkers that guide personalized cancer treatments. These tests, such as HER2 testing in breast cancer, determine eligibility for targeted therapies like trastuzumab. The evolving landscape of CDx tests is marked by decreasing costs, driven by technological advancements and economies of scale, enhancing accessibility and effectiveness in tailored cancer care worldwide, according to GlobalData, a leading data and analytics company.

GlobalData’s report, “HER2 Tests Market Forecast to 2033,” reveals that the market for HER2 tests will grow at a compound annual growth rate (CAGR) of more than 1% from 2023 to 2033. This growth is driven by factors such as the rising incidence of breast and gastric cancer, greater disease awareness, improved accessibility to companion diagnostics in emerging economies, and technological advancements. In 2023, the HER2 tests market was valued at $123.6 million and is expected to continue growing steadily over the next decade.

Technological Advancements and Economies of Scale Drive Down Costs of Companion Diagnostics

Tina Deng, MSc, Principal Medical Devices Analyst at GlobalData, comments: “The pricing trend of CDx tests is generally towards decreasing costs, driven by technological advancements, economies of scale, and increased competition. However, the initial cost of new and innovative tests may be higher until they achieve broader adoption and market penetration. As the adoption of CDx tests grows, the higher volume of tests performed leads to economies of scale, reducing the per-test cost. By enabling more effective and tailored treatments, CDx tests can reduce overall healthcare costs by avoiding ineffective treatments and minimizing adverse drug reactions.”

Efforts are being made to improve access to affordable companion diagnostics, particularly in developing countries. The cost of companion diagnostics can vary widely depending on the type of test, technology complexity, and regulatory requirements. Common test types include protein expression tests such as immunohistochemistry, PCR-based tests, and fluorescence in situ hybridization. Deng also highlights that the cost of next-generation sequencing has been decreasing significantly due to improvements in sequencing technology, higher throughput, and greater efficiency, making multi-gene panels and comprehensive genomic profiling more affordable.

Companion Diagnostics

Rising Cancer Rates and CDx Advancements to Drive Global Growth in HER2 Tests Market

The report also covers the market dynamics, noting that the market for HER2 amplification tests will grow across all regions during the forecast period. This growth is attributed to rising cancer incidence, greater disease awareness, and improved accessibility to companion diagnostics in emerging economies. The use of immunohistochemistry (IHC) and in situ hybridization (ISH) remains essential in determining HER2 status, while next-generation sequencing (NGS) is gaining popularity, especially in Europe.

In 2023, Europe emerged as the leading region in the HER2 tests market, with the European Society for Medical Oncology (ESMO) recommending HER2 gene amplification status be determined from all invasive breast cancer tumors and advanced, metastatic gastric adenocarcinoma for targeted therapy. The report also identifies key players in the market, including Foundation Medicine Inc., Agilent Technologies Inc., Abbott Laboratories, Leica Biosystems Nussloch GmbH, and MilliporeSigma + Sigma Aldrich.

In conclusion, the rising prevalence of cancer and advancements in CDx technology are set to drive significant growth in the HER2 tests market. The introduction of affordable and accessible companion diagnostics is a critical step towards making personalized cancer care more effective and widespread. As the market continues to evolve, the collaboration between healthcare providers, regulatory bodies, and pharmaceutical companies will be essential in addressing the challenges of cancer treatment and improving patient outcomes worldwide.


You can follow our news on our Telegram and LinkedIn accounts.

Resource: GlobalData, July 02, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article